FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367305052> ?p ?o ?g. }

• W4367305052 abstract "<h3>Objective:</h3> To assess the diagnostic performance of the Boston criteria version 2.0 for cerebral amyloid angiopathy (CAA) diagnosis in a cohort of individuals without symptomatic intracerebral hemorrhage or CAA-related transient focal neurological episodes (TFNE) and who had pathological assessment for CAA. <h3>Background:</h3> The Boston criteria were recently updated to incorporate non-hemorrhagic MRI biomarkers of CAA and small vessel disease. The updated criteria (v2.0) demonstrated improved diagnostic yield when compared to prior versions of the criteria (v1.5) among patients presenting with symptomatic CAA-related syndromes. However, these criteria have not been validated in any cohorts without symptomatic CAA. <h3>Design/Methods:</h3> Fifty-four participants with a median age of 75, followed in large population-based or observational studies, were included if they had an antemortem MRI with gradient-recall echo sequences and a subsequent brain autopsy with CAA evaluation. Performance of the Boston criteria v2.0 was compared to v1.5 using pathologically verified CAA as the reference standard. Performance measures were calculated using a logistic regression. Paired AUC were compared using the pROC package in R. <h3>Results:</h3> Overall, 28/54 participants had pathologically confirmed CAA (i.e. moderate-to-severe CAA in at least 1 cortical region). The sensitivity and specificity of the Boston criteria v2.0 were 78.6% (59.1–91.7) and 34.6% (17.2–55.7) for any CAA diagnosis (possible + probable; AUC: 0.57) and 28.6% (13.2–48.7) and 69.2% (48.2–85.7) for probable CAA diagnosis (AUC 0.49), respectively. The v2.0 Boston criteria had superior accuracy to the prior v1.5 criteria for any CAA diagnosis (AUC 0.57 [0.45–0.69] vs. AUC 0.43 [0.30–0.56], <i>Z</i>= 2.10, <i>p</i>= 0.03). <h3>Conclusions:</h3> The Boston criteria v2.0 have limited accuracy for CAA diagnosis in an asymptomatic population. Additional biomarkers may need to be explored in this setting to optimize CAA diagnostic performance. <b>Disclosure:</b> Dr. Switzer has nothing to disclose. Dr. Charidimou has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Imperative Care. Dr. Charidimou has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier, Journal of Neurological Sciences. Dr. McCarter has nothing to disclose. Scott Przybelski has nothing to disclose. Timothy Lesnick has received personal compensation for serving as an employee of Mayo Clinic. Dr. Vemuri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Miller Medical Communications Inc.. The institution of Dr. Vemuri has received research support from NIH. The institution of Ross Reichard has received research support from NIH. An immediate family member of Ross Reichard has received publishing royalties from a publication relating to health care. Dr. Rabinstein has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific. Dr. Rabinstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra Zeneca. Dr. Rabinstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NovoNordisk. Dr. Rabinstein has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurocritical care/NCS-Springer. Dr. Rabinstein has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters/UptoDate. Dr. Rabinstein has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for EBSCO/DynaMed. Dr. Rabinstein has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AHA. The institution of Dr. Rabinstein has received research support from EyeBox. The institution of Dr. Rabinstein has received research support from Chiesi. The institution of Dr. Rabinstein has received research support from Alexion. Dr. Rabinstein has received publishing royalties from a publication relating to health care. Dr. Rabinstein has received publishing royalties from a publication relating to health care. Dr. Rabinstein has received publishing royalties from a publication relating to health care. Dr. Rabinstein has received publishing royalties from a publication relating to health care. Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nestle. Dr. Petersen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech, Inc.. Dr. Petersen has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche, Inc.. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. The institution of Dr. Graff-Radford has received research support from NIH." @default.
• W4367305052 created "2023-04-29" @default.
• W4367305052 creator A5000120538 @default.
• W4367305052 creator A5005572080 @default.
• W4367305052 creator A5016561542 @default.
• W4367305052 creator A5026250910 @default.
• W4367305052 creator A5031126927 @default.
• W4367305052 creator A5031713672 @default.
• W4367305052 creator A5043921358 @default.
• W4367305052 creator A5048006717 @default.
• W4367305052 creator A5057493616 @default.
• W4367305052 creator A5059027860 @default.
• W4367305052 creator A5089312897 @default.
• W4367305052 date "2023-04-25" @default.
• W4367305052 modified "2023-10-17" @default.
• W4367305052 title "Diagnostic Value of the Boston criteria v2.0 for Cerebral Amyloid Angiopathy in Individuals Without Hemorrhage: An MRI-neuropathological Validation Study (S15.009)" @default.
• W4367305052 doi "https://doi.org/10.1212/wnl.0000000000203322" @default.
• W4367305052 hasPublicationYear "2023" @default.
• W4367305052 type Work @default.
• W4367305052 citedByCount "0" @default.
• W4367305052 crossrefType "proceedings-article" @default.
• W4367305052 hasAuthorship W4367305052A5000120538 @default.
• W4367305052 hasAuthorship W4367305052A5005572080 @default.
• W4367305052 hasAuthorship W4367305052A5016561542 @default.
• W4367305052 hasAuthorship W4367305052A5026250910 @default.
• W4367305052 hasAuthorship W4367305052A5031126927 @default.
• W4367305052 hasAuthorship W4367305052A5031713672 @default.
• W4367305052 hasAuthorship W4367305052A5043921358 @default.
• W4367305052 hasAuthorship W4367305052A5048006717 @default.
• W4367305052 hasAuthorship W4367305052A5057493616 @default.
• W4367305052 hasAuthorship W4367305052A5059027860 @default.
• W4367305052 hasAuthorship W4367305052A5089312897 @default.
• W4367305052 hasConcept C126322002 @default.
• W4367305052 hasConcept C126838900 @default.
• W4367305052 hasConcept C142724271 @default.
• W4367305052 hasConcept C143409427 @default.
• W4367305052 hasConcept C146638467 @default.
• W4367305052 hasConcept C151956035 @default.
• W4367305052 hasConcept C207886595 @default.
• W4367305052 hasConcept C2777094939 @default.
• W4367305052 hasConcept C2777736543 @default.
• W4367305052 hasConcept C2777790613 @default.
• W4367305052 hasConcept C2779134260 @default.
• W4367305052 hasConcept C2779483572 @default.
• W4367305052 hasConcept C2908647359 @default.
• W4367305052 hasConcept C40993552 @default.
• W4367305052 hasConcept C71924100 @default.
• W4367305052 hasConcept C72563966 @default.
• W4367305052 hasConcept C99454951 @default.
• W4367305052 hasConceptScore W4367305052C126322002 @default.
• W4367305052 hasConceptScore W4367305052C126838900 @default.
• W4367305052 hasConceptScore W4367305052C142724271 @default.
• W4367305052 hasConceptScore W4367305052C143409427 @default.
• W4367305052 hasConceptScore W4367305052C146638467 @default.
• W4367305052 hasConceptScore W4367305052C151956035 @default.
• W4367305052 hasConceptScore W4367305052C207886595 @default.
• W4367305052 hasConceptScore W4367305052C2777094939 @default.
• W4367305052 hasConceptScore W4367305052C2777736543 @default.
• W4367305052 hasConceptScore W4367305052C2777790613 @default.
• W4367305052 hasConceptScore W4367305052C2779134260 @default.
• W4367305052 hasConceptScore W4367305052C2779483572 @default.
• W4367305052 hasConceptScore W4367305052C2908647359 @default.
• W4367305052 hasConceptScore W4367305052C40993552 @default.
• W4367305052 hasConceptScore W4367305052C71924100 @default.
• W4367305052 hasConceptScore W4367305052C72563966 @default.
• W4367305052 hasConceptScore W4367305052C99454951 @default.
• W4367305052 hasLocation W43673050521 @default.
• W4367305052 hasOpenAccess W4367305052 @default.
• W4367305052 hasPrimaryLocation W43673050521 @default.
• W4367305052 hasRelatedWork W1575204576 @default.
• W4367305052 hasRelatedWork W1986281881 @default.
• W4367305052 hasRelatedWork W2084821680 @default.
• W4367305052 hasRelatedWork W2094899106 @default.
• W4367305052 hasRelatedWork W2159173382 @default.
• W4367305052 hasRelatedWork W2485222321 @default.
• W4367305052 hasRelatedWork W2744601449 @default.
• W4367305052 hasRelatedWork W2904954755 @default.
• W4367305052 hasRelatedWork W2914926994 @default.
• W4367305052 hasRelatedWork W2966120825 @default.
• W4367305052 isParatext "false" @default.
• W4367305052 isRetracted "false" @default.
• W4367305052 workType "article" @default.